No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
BDTX Black Diamond Therapeutics
- 6.110
- -0.640-9.48%
Close May 10 16:00 ET
- 5.750
- -0.360-5.89%
Post 17:46 ET
343.70MMarket Cap-3680P/E (TTM)
6.880High6.045Low547.16KVolume6.600Open6.750Pre Close3.47MTurnover1.35%Turnover RatioLossP/E (Static)56.25MShares7.66052wk High3.30P/B247.31MFloat Cap1.57052wk Low--Dividend TTM40.48MShs Float46.250Historical High--Div YieldTTM12.37%Amplitude1.180Historical Low6.335Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Black Diamond Therapeutics Expects Cash & Equivalents Of $115.2M As Of March-End To Be Sufficient To Fund Operations Into Q3 Of 2025
Express News | Black Diamond Therapeutics Inc: Cash, Cash Equivalents, and Investments of $115.2 Mln as of March 31, 2024
Black Diamond Theraptcs 1Q Research and Development Expenses $13.5M >BDTX
Black Diamond Theraptcs 1Q Research and Development Expenses $13.5M >BDTX
Express News | Black Diamond Therapeutics Q1 Net Income USD -18.225 Million
Express News | Black Diamond Therapeutics Q1 Operating Expenses USD 20.246 Million
Express News | Black Diamond Therapeutics Q1 Basic EPS USD -0.35
Comments
$Black Diamond Therapeutics(BDTX.US$
NEWS
Black Diamond Therapeutics, Inc. presents real-world data at AACR Annual Meeting showcasing the potential of BDTX-1535, the most advanced fourth-generation oral TKI, to target a wide range of classical, non-classical, and C797S resistance EGFR mutations in NSCLC patients. The compound demonstrates potent inhibition of over 50 clinically relevant non-classical EGFR mutations and the C797S resistance mutation, offering a promising treatment option for EGF...
NEWS
Black Diamond Therapeutics, Inc. presents real-world data at AACR Annual Meeting showcasing the potential of BDTX-1535, the most advanced fourth-generation oral TKI, to target a wide range of classical, non-classical, and C797S resistance EGFR mutations in NSCLC patients. The compound demonstrates potent inhibition of over 50 clinically relevant non-classical EGFR mutations and the C797S resistance mutation, offering a promising treatment option for EGF...
2
$Black Diamond Therapeutics(BDTX.US$ moving 👀 lot of 💰 holders at 5/6$ past spike !
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg